Adamis Pharmaceuticals Corp (ADMP)
0.119
0.00 (0.00%)
USD |
NASDAQ |
Mar 24, 16:00
0.1188
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 19.78M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -80.32% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.670 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.41% |
News
Headline
Wire
Time (ET)
Globe Newswire
03/16 16:24
Globe Newswire
03/14 16:01
PR Newswire
03/01 21:10
Globe Newswire
03/01 08:51
PR Newswire
02/28 13:18
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/31/2023* | 14:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/31/2023* | -- | Results | Q4 2022 | -- | -0.02 | -- | |
| 08/10/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/10/2022 | -- | Results | Q2 2022 | -0.06 | -0.04 | -50.00% | |
| 05/16/2022 | 17:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/16/2022 | -- | Results | Q1 2022 | -0.07 | -0.03 | -133.3% | |
| 03/31/2022 | -- | Results | Q4 2021 | -0.06 | -0.05 | -20.00% | |
| 03/31/2022 | 17:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19. |
| URL | https://www.adamispharmaceuticals.com |
| Investor Relations URL | http://ir.adamispharmaceuticals.com/phoenix.zhtml?c=99350&p=irol-irhome |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 31, 2023 (est.) |
| Last Earnings Release | Aug. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 4.851M |
| Total Expenses (TTM) | 29.91M |
| Net Income (TTM) | -26.48M |
| Total Assets (Quarterly) | 10.93M |
| Total Liabilities (Quarterly) | 11.74M |
| Shareholders Equity (Quarterly) | -0.8081M |
| Cash from Operations (TTM) | -25.90M |
| Cash from Investing (TTM) | 3.484M |
| Cash from Financing (TTM) | 0.285M |
Ratings
Profile
Edit
| Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19. |
| URL | https://www.adamispharmaceuticals.com |
| Investor Relations URL | http://ir.adamispharmaceuticals.com/phoenix.zhtml?c=99350&p=irol-irhome |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 31, 2023 (est.) |
| Last Earnings Release | Aug. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ADMP Tweets |